Stage III-IV SCCHN and select stage II participants (TN oral cavity cancer with >  mm depth invasion)
Histologically-proven diagnosis of advanced (American Joint Committee on Cancer [AJCC], th addition: stage III or IV) or aggressive (published disease-specific survival rates less than % at  years following best currently available therapies) solid organ cancer; this includes but is not limit to: \r\n* Metastatic melanoma\r\n* Esophageal and gastric adenocarcinoma (stage III/IV)\r\n* Cholangiocarcinoma (any stage)\r\n* Pancreatic adenocarcinoma (any stage)\r\n* Gallbladder cancer (any stage)\r\n* Colorectal cancer (stage IV)\r\n* High-grade mucinous appendix cancer (any stage)\r\n* High-grade gastrointestinal neuroendocrine cancer (any stage)\r\n* Mesothelioma (any stage)\r\n* High-grade soft tissue sarcoma (any stage)
Eligible tumors must meet one of the following criteria: Stage II or III, or T, any N, M, including clinical or pathologic inflammatory cancer or Regional Stage IV, where supraclavicular lymph nodes are the only sites metastasis
Stage  cancer
Female subjects with CA-associated, advanced ovarian cancer (FIGO Stage III/IV) previously treated and now presenting with recurrent or persistent disease.
AJCC stage III/IV differentiated thyroid cancer
Clinical stage IV cancer
Colon cancer stages I-II and IV or rectal cancer stage I or IV
Patients with biopsy-proven adenocarcinoma, stage II- IV rectal cancer.
Have histologically proven diagnosis of non-small cell lung cancer (NSCLC) (stage III and stage IV [to include limited volume metastases such as brain, bone, adrenal])
Subjects with FIGO Stage Ic, Stage II, Stage III, Stage IV, recurrent, or persistent (unresectable) histologically confirmed epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube carcinoma.
Patients with selected Stage III or IV disease (T N- M, T- any N M, T Nb, Nc or Np negative oropharynx cancer or T- any N hypopharynx cancer) including no distant metastases.
Stage IV or recurrent pancreatic cancer by imaging
Patients must have locally advanced unresectable stage IIIC or metastatic stage IV cancer with either progression to prior therapy or a newly diagnosed cancer that does not have an available treatment with curative intent
Prior therapy before Day  of Cycle  for the treatment of Stage IV pancreatic cancer
Prior therapy before Day  of Cycle  for the treatment of Stage IV pancreatic cancer
Participants must have clinical diagnosis of lung or bladder cancer; if the diagnosis of non-small cell lung cancer (NSCLC) or bladder cancer is confirmed, platinum-based chemotherapy must be planned either for neoadjuvant chemotherapy for stage II or above bladder cancer, or palliative therapy for stage III or IV bladder cancer or stage IV lung cancer regardless of patient participation in this study; stage II or above transitional cell carcinoma (TCC) patients and stage IV NSCLC patients that will receive platinum-based chemotherapy will be eligible for this study; patients with stage III or IV bladder cancer or stage IV lung cancer must have measurable lesion(s)
Stage IV cancer
Diagnosis of an advanced solid tumor malignancy (advanced cancer) or lymphoma; in most situations, this would be a stage IV cancer; patients with a diagnosis of stage III cancer or lymphoma are eligible if cure is not possible or anticipated; clinical staging without pathological confirmation of advanced disease is allowed
Cancer stage: T - N x M
Diagnosed with stage III or IV colorectal cancer
Stage IV and/or metastatic solid tumor cancer diagnosis, or stage III pancreatic or lung cancer diagnosis
Diagnosis of adenocarcinoma colorectal cancer (stage I, II, III, IV)
Patients must have stage III or IV cancer diagnosis
Diagnosis of an advanced solid tumor malignancy (advanced cancer) or lymphoma; in most situations, this would be a stage IV cancer; a patient with a diagnosis of stage III cancer or lymphoma is eligible if cure is not possible or anticipated; clinical staging without pathological confirmation of advanced disease is allowed
Women diagnosed with stage I-IV ovarian cancer
Diagnosed with stage I-II endometrial cancer
History of endometrial cancer stage I-IV >  months <  years, not currently receiving cancer treatment
Have been diagnosed within one month with a pathologically confirmed advanced cancer who have an average of <  year (y) life expectancy (primary stage IV hepatobiliary, esophageal, colorectal, glioblastoma, gastric, pancreatic, melanoma, head and neck, or stage III or IV lung or pancreatic cancers) and are being treated at one of the participating hospital sites and speak English or Spanish
Stage III/IV cancer
Diagnosis of stage III-IV epithelial ovarian cancer (EOC)
Histologic or cytologic confirmation of head & neck cancer (stage I-IV) or non-small cell lung cancer (stage II & III)
Stage I-IV gynecologic cancer (including ovarian, uterine, cervical, vulvar, or vaginal cancer)
Spouses of women with diagnosed within the past  months with stage III or IV ovarian cancer will be eligible to participate, as will the diagnosed wife/partner
Women diagnosed with stage IV ovarian cancer and who are hospice eligible
Diagnosis of stage III or stage IV cancer
Diagnosed with stage I-III cancer other than cancers of the brain or spinal cord (confirmed by patient self-report on the Health History Questionnaire; if patient is unable to confirm either the site of her cancer or that her stage of cancer is < stage IV, we will send a letter to her physician to confirm this criterion)
Scheduled for surgery at Brigham and Womens Hospital for known or highly suspected stage III or IV ovarian cancer (i.e. elevated cancer antigen [CA]- with a pelvic mass, ascites, and carcinomatosis)
Stage II-IV epidermoid cancer of the head and neck OR stage III-IV pancreatic cancer, with prognosis of at least three months, per oncologist
A treatment plan involving levels I-III, I-IV, II-III, or II-IV, as recommended by National Comprehensive Cancer Network (NCCN) guidelines
Newly diagnosed patients for the following conditions\r\n* Colon cancer stage III and IV\r\n* Rectal cancer stage II, III, IV\r\n* Glioblastoma multiforme (brain) -- no stage\r\n* Non-small cell lung cancer stage IIIA, IIIB, IV\r\n* Small cell lung cancer, limited stage and extensive stage\r\n* Castration-resistant prostate cancer\r\n* Head and neck cancer stage III and IV\r\n* Gastric cancer stage III and IV\r\n* Esophageal cancer stage III and IV\r\n* Pancreatic cancer stage II, III, IV\r\n* Renal cell carcinoma, stage IV\r\n* Breast cancer, stage IV, if triple negative ER/PR/HN negative or on systemic chemotherapy\r\n* Sarcoma, stage IV\r\n* Bladder carcinoma, stage IV\r\n* Acute myeloid leukemia\r\n* Melanoma, stage III and IV\r\n* Ovarian cancer, stage III and IV\r\n* High grade myelodysplastic syndrome (MDS)
Known Stage IV ovarian cancer with Brain Metastases